Phaseline

Companies › Allyx Therapeutics

Allyx Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BMS-984923
CYP3A4 inhibitor (presumed based on drug-drug interaction study design)
–Phase 1Drug Drug Interaction (DDI)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06632990BMS-984923Phase 1Drug Drug Interaction (DDI)OtherApr 2025

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.